Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists.

Journal des maladies vasculaires - 1 Jul 2014

Béné J, Dubart A-E, Senis C, Auffret M, Caron J, Gautier S

Abstract excerpt

AIM: To identify, in a case-control study, the risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists. MATERIALS AND METHODS: We performed a single-centre observational study during a three-month period where we consecutively included patients admitted to the emergency department of a secondary-level hospital and treated with vitamin K antagonists, regardless...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Drug Interactions
Share to Emergency Service, Hospital

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to International Normalized Ratio

Share to Respiration Disorders

Share to Vitamin K

Share to Warfarin

Source

Identifiers

PMID: 24889788
DOI: 10.1016/j.jmv.2014.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists.PMID 24889788Read ↗

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.Semantic proximity Read ↗

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countriesSemantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.Semantic proximity Read ↗

Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.Semantic proximity Read ↗

Gastrointestinal Bleeding During Direct Oral Anticoagulants Therapy in Patients With Nonvalvular Atrial Fibrillation and Risk of PolypharmacySemantic proximity Read ↗

Appropriateness of using vitamin K for the correction of INR elevation secondary to hepatic disease in critically ill patients: An Observational StudySemantic proximity Read ↗

Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.Semantic proximity Read ↗

Bleeding in cardiac patients prescribed antithrombotic drugs: Electronic health record phenotyping algorithms, incidence, trends and prognosisSemantic proximity Read ↗

Characterizing the thrombotic spectrum and clinical phenotypes of tranexamic acid-associated adverse events: a pharmacovigilance study based on the FAERS databaseSemantic proximity Read ↗

Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.Semantic proximity Read ↗

Association of Oral Triptans and Other Oral Migraine Treatments With Cardiovascular Outcomes in Patients With a History of Cardiovascular ConditionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.